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Matrix Research Group, Department of Pathology and Medical Biology, University Medical Center Groningen, University of 
Groningen, Groningen, Netherlands
Chronic organ injury leads to fibrosis and eventually organ failure. Fibrosis is characterized 
by excessive synthesis, remodeling, and contraction of extracellular matrix produced by 
myofibroblasts. Myofibroblasts are the key cells in the pathophysiology of fibrotic disor-
ders and their differentiation can be triggered by multiple stimuli. To develop anti-fibrotic 
therapies, it is of paramount importance to understand the molecular basis of the signal-
ing pathways contributing to the activation and maintenance of myofibroblasts. Several 
signal transduction pathways, such as transforming growth factor (TGF)-β, Wingless/Int 
(WNT), and more recently yes-associated protein 1 (YAP)/transcriptional coactivator with 
PDZ-binding motif (TAZ) signaling, have been linked to the pathophysiology of fibrosis. 
Activation of the TGF-β1-induced SMAD complex results in the upregulation of genes 
important for myofibroblast function. Similarly, WNT-stabilized β-catenin translocates 
to the nucleus and initiates transcription of its target genes. YAP and TAZ are two 
transcriptional co-activators from the Hippo signaling pathway that also rely on nuclear 
translocation for their functioning. These three signal transduction pathways have little 
molecular similarity but do share one principle: the cytosolic/nuclear regulation of its 
transcriptional activators. Past research on these pathways often focused on the isolated 
cascades without taking other signaling pathways into account. Recent developments 
show that parts of these pathways converge into an intricate network that governs the 
activation and maintenance of the myofibroblast phenotype. In this review, we discuss 
the current understanding on the signal integration between the TGF-β, WNT, and YAP/
TAZ pathways in the development of organ fibrosis. Taking a network-wide view on 
signal transduction will provide a better understanding on the complex and versatile 
processes that underlie the pathophysiology of fibrotic disorders.
Keywords: fibrosis, myofibroblast, TGF-β, wNT, YAP/TAZ, Hippo, signaling
introduction
Regardless of the initial trigger, chronic organ injury disturbs the cellular and molecular processes 
of normal wound healing, resulting in organ fibrosis and eventually organ failure (1). Chronic 
injury causes prolonged activation of effector cells, such as fibroblasts (2), pericytes (3–5), bone 
marrow-derived cells (6–8), and possibly cells from epithelial (9) or endothelial origin (10, 11), 
which differentiate toward myofibroblasts. In normal granulation tissue, myofibroblasts are essential 
for the deposition, contraction, and remodeling of the extracellular matrix (ECM) and thereby 
promote wound healing (12). However, aberrant wound healing results in increased proliferation 
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and attenuated apoptosis of myofibroblasts. The well-developed 
cytoskeletal apparatus of myofibroblasts contains actin and 
myosin, which are linked to the so-called supermature focal 
adhesions that connect the cells actin filaments to the ECM (13). 
This allows myofibroblasts to contract the ECM around them 
and create contractures that impede organ function (14). The de 
novo expression of smooth muscle α-actin (αSMA), an isoform 
usually expressed in smooth muscle cells, further enhances their 
contractile capabilities (15, 16). Moreover, myofibroblasts are 
notorious producers of ECM components, such as collagens, 
glycoproteins, and proteoglycans, resulting in the formation of 
fibrous scar tissue. Cross-linking of collagen in fibrous scar tissue 
makes it highly resistant to protease degradation and results in 
irreversible scarring and destruction of the tissue architecture 
(17). Although a large body of knowledge exists on myofibroblast 
biology, as of to date, no approved therapies are available that 
can reverse fibrosis (18, 19). Thus, understanding the molecular 
mechanisms that govern the differentiation and maintenance of 
myofibroblasts in fibrotic diseases is of paramount importance.
The differentiation of myofibroblasts is governed by an 
interplay between different mechanisms. Under increased tissue 
stiffness and mechanical strain, fibroblasts become activated and 
show increased β- and γ-actin and αSMA-containing stress fibers, 
linked to focal adhesions (15). They also start to express the ED-A 
splice variant of cellular fibronectin – crucial for myofibroblast 
differentiation  –  at the plasma membrane (20, 21). Membrane 
protruding integrin molecules connect the ECM components to 
the actin fibers, which allows for the conversion of mechanical 
into biochemical cues that are relayed to the nucleus.
Alternatively, myofibroblast differentiation is driven by bio-
chemical signaling of extracellular growth factors. Many growth 
factor families have been studied extensively in the context of 
organ fibrosis, with an emphasis on the transforming growth 
factor (TGF)-β and Wingless/Int (WNT) signaling pathways as 
key mediators [reviewed in Ref. (22, 23)]. Their mode of action 
describes the production of soluble growth factor ligands by a 
variety of cell types. The growth factors are stored in the ECM, 
until they are activated and released by mechanical tension or 
proteolytic cleavage, which enables these ligands to engage their 
membrane-bound receptors. The receptors relay the biochemical 
signal inwards, via kinase complexes, to the nucleus. Nuclear 
transcriptional modulators then act on the chromatin complex 
in order to change the transcriptional landscape, and thereby pro-
mote or repress transcription of target genes. Recently, in fibrosis 
research the attention shifted toward a relatively new signaling 
cascade: yes-associated protein 1 (YAP)/transcriptional coactiva-
tor with PDZ-binding motif (TAZ) signaling. Interestingly, the 
three mentioned signal transduction pathways have but little 
molecular similarity but do share one principle: the cytosolic/
nuclear regulation of their transcriptional modulators.
In the past, signaling cascades were often studied in isola-
tion, i.e., a ligand signals through its receptor and mediates the 
nuclear accumulation of one or several transcription factors to 
modulate target gene expression. This view changed since recent 
advances suggest that these cascades are in fact organized into 
complex signaling networks which, dependent on the cellular 
and environmental context, govern cell function and fate in 
fibrotic disorders. This inter-pathway communication allows for 
increased versatility and fine tuning of cellular responses, which 
may explain the variety of phenotypes found in fibrotic disorders. 
The aim of this review is to discuss the current understanding on 
the signal integration between the TGF-β, WNT, and YAP/TAZ 
pathways in the development of fibrosis. We will start with a short 
overview of the three pathways, and extend our discussion with a 
detailed view on how these pathways connect at multiple levels of 
signal transduction in the context of myofibroblast function and 
fibrosis. Finally, we touch upon the challenges and considerations 
in the design of anti-fibrotic therapies, with focus on the cross-
talk between the three signal transduction cascades.
Canonical TGF-β Signaling
The TGF-β superfamily of growth factors consists of multiple 
proteins that govern a wide range of physiological processes, such 
as stem cell pluripotency, cell fate determination, proliferation, 
and differentiation. In humans, over 30 members of the TGF-β 
superfamily have been documented, including TGF-βs, activins, 
inhibins, nodal, growth/differentiation factors (GDFs), and bone 
morphogenetic proteins (BMPs). In this review, we focus mainly 
on the canonical signaling through TGF-β1, since considerable 
evidence exists for its role in fibrosis (22) (Figure 1).
In homeostatic conditions, TGF-β is trapped in the ECM 
together with latency-associated peptides (LAPs) and latent 
TGF-β-binding proteins (LTBPs) in the so-called large latent 
complex (LLC) (24). Upon injury, proteolytic cleavage of the LAP 
(25), or binding of integrins together with increased mechanical 
forces (26–28), cause release of TGF-β from the LLC allowing 
it to engage its receptors. Signaling propagation occurs when 
a TGF-β homodimer interacts with two type I and two type II 
receptors. Ligand binding initiates the phosphorylation of the 
SGSGSG domain on the type I receptor by the type II receptor 
(29, 30). Subsequently, the activated type I receptor is now able to 
bind and phosphorylate Smad proteins, the central modulators 
of canonical TGF-β signaling. There are three classes of Smad 
proteins: regulatory (R)-Smads, co-activator (Co)-Smads, and 
inhibitory (I)-Smads. R-Smads (Smad2 and Smad3) are phospho-
rylated by the type I receptor and form heteromeric complexes 
with the Co-Smad, Smad4. Both R-Smads and Smad4 consist of a 
N-terminal MH1 and a C-terminal MH2 domain connected by a 
linker region. Upon phosphorylation of the MH2 domain, Smad 
complexes shuttle to the nucleus and together with DNA-binding 
proteins (31–33) localize to specific CAGAC motifs, the so-called 
Smad-binding elements (SBE), to regulate transcription of target 
genes (34).
There is ample evidence that TGF-β signaling is a key regulator 
of myofibroblast biology in the heart, lungs, liver, kidneys, and skin 
(35–49). TGF-β levels are elevated in fibrotic tissues and myofibro-
blasts display nuclear accumulation of Smads in vivo accompanied 
with an increased expression of TGF-β target genes and decreased 
levels of the inhibitory Smad6 and Smad7. Despite a tremendous 
body of experimental work, the mechanisms underlying Smad-
induced fibroblast activation are incompletely understood, as 
both activation and inhibition of Smads can promote fibrogenesis, 
dependent on the context (37, 47, 50–55). Furthermore, inhibition 
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of the Smad signaling cascade does not completely attenuate the 
fibrotic response, which suggests that several other signaling 
cascades are involved in activating the transcriptional program of 
myofibroblasts. It has become evident that transcriptional output 
of Smad signaling is tightly controlled by the interplay with a 
variety of master transcription factors, DNA-binding (co)factors, 
repressors, and chromatin readers, and writers (33, 56).
Canonical wNT Signaling
Discovered in Sophophora (Drosophila) as Wingless and in the 
mouse as Int1, together termed WNT in mammals, canonical 
WNT signaling comprises the molecular interactions leading to 
the nuclear translocation of β-catenin [reviewed in Ref. (23, 57)] 
(Figure 2). WNTs have primarily been studied in fetal develop-
ment as they are responsible for the formation and polarity of the 
primary body axis (58), but it has become evident that they are 
versatile growth factors in both homeostasis and disease. Soluble 
WNT ligands bind to a family of seven transmembrane receptors 
FiGURe 1 | Canonical TGF-β signaling in fibrosis. (A) Transforming 
growth factor-β (TGF-β) homodimers engage the type II receptors, which 
phosphorylate and form a heterotetrameric complex with two type I receptors 
and additional Smad-binding proteins such as SARA. The signaling domain 
of the type I receptor mediates phosphorylation and activation of Smad 
proteins. (B) Smad4 associates with phosphorylated Smads to form an 
active heterotrimeric complex. (C) The inhibitory Smad7 together with 
Smad-specific E3 ubiquitin protein ligases (Smurf) inhibits the receptor 
complex by targeting it for ubiquitination and proteasomal degradation. 
(D) The activated Smad complex forms a transcriptional module with several 
transcription factors, co-factors such as p300 and Creb binding protein 
(CBP) to promote transcription of target genes (e.g., PAI1, COL1A1, CCN2). 
(e) Dephosphorylated Smad proteins continuously shuttle between the 
nucleus and the cytoplasm. In the cytoplasm, they can be targeted for 
degradation by ubiquitin ligases. (F) Consecutive phosphorylation by CDK8/9 
and GSK3 in the nucleus recruits the ubiquitin ligase Nedd4L that target 
Smad proteins for proteasomal degradation in the cytoplasm, and possibly 
the nucleus.
named Frizzled (Fz). A single WNT ligand can interact with 
several Fz receptors, and vice versa (59). In a WNT-off state, the 
concentration of endogenous WNT antagonists outweighs that 
of WNT ligands, which results in the phosphorylation of cyto-
plasmic β-catenin by two subunits from the β-catenin destruction 
complex, glycogen synthase kinase (GSK)3, and casein kinase 
(CK)1. These phosphorylation events trigger subsequent ubiq-
uitination and proteasomal degradation of β-catenin (60). In a 
WNT-on state, ligands engage the Fz receptors which function 
together with the low-density-lipoprotein-receptor-related pro-
teins (LRP)5 and LRP6 co-receptors to activate the downstream 
signaling cascade. LRP is phosphorylated in its cytoplasmic tail 
by GSK3 and CK1 proteins (61–63). The activated Fz/LRP com-
plex interacts with Disheveled (DVL), Axin, and GSK3 through 
Pro-Pro-Pro-(Ser/Tyr)-Pro repeats (62, 63). Axin functions as a 
scaffold for the destruction complex, as it directly interacts with 
β-catenin, GSK3, CK1, the tumor suppressor protein adenoma-
tous polyposis coli (APC), and the ubiquitin ligase β-TrCP. As 
Axin and GSK3 are sequestered to the plasma membrane by 
FiGURe 2 | Active canonical wNT signaling in fibrosis. Simplified scheme 
showing the activated canonical WNT cascade and translocation of β-catenin. 
(A) WNT ligands bind to a frizzled receptor and form a complex with the 
co-receptor Lipoprotein-related-receptor protein (LRP). (B) The ubiquitination 
activity of the destruction complex [comprised of disheveled (DVL) Axin, 
adenomatous polyposis coli (APC), glycogen synthase kinase 3 (GSK3), and 
casein kinase 1(CK1)] is inhibited causing β-catenin to accumulate in the 
cytoplasm. (C) As later event, clusters of receptor complexes are internalized 
into endosomes, which triggers the sequestering of the destruction complex, 
and subsequent inhibition of GSK3. (D) GSK3 is then transported to 
multivesicular bodies where it cannot interact with cytoplasmic β-catenin, and 
thus protects β-catenin from proteasomal degradation. (e) Newly synthesized 
β-catenin translocates to the nucleus to interact with LEF/TCF transcription 
factors and other co-factors, such as p300 and CBP. (F) Termination of the 
WNT/β-catenin signaling cycle may occur through phosphorylation of 
β-catenin by protein kinase C (PKC)δ and subsequent ubiquitination by 
tripartite motif (TRIM)33. These steps target β-catenin for 
proteasomal degradation in the nucleus. (G) Another possible route for the 
termination of β-catenin activation is the cytoplasmic sequestering by 14-3-3ζ 
and Chibby (Cby).
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the Fz/LRP complex, β-TrCP is excluded from the destruction 
complex, limiting β-catenin ubiquitination and degradation (64). 
An alternative route of WNT activation describes the formation 
of LRP5/6 aggregates that are internalized together with the 
destruction complex in the so-called multivesicular bodies. Once 
inside the multivesicular bodies, a large portion of β-catenin 
cannot interact with the destruction complex and thus escapes 
ubiquitination (65, 66). Stabilized β-catenin now accumulates 
in the nucleus where it associates with T-cell factor/lymphoid 
enhancer-binding factor-1 (TCF/Lef-1) transcription factors and 
several co-factors like p300 and CREB binding protein (CBP) to 
regulate transcription of target genes (67, 68).
About 10 years ago, the first evidence of WNT involvement in 
myofibroblast biology was found (69). Since then, many studies 
have emphasized a key role for canonical WNT signaling in fibro-
genesis of the heart, lungs, kidneys, and several fibrotic disorders 
of the skin (70–86). Aberrant activation of WNT signaling can 
be caused by increased expression of WNT agonists (87), or by 
silencing of endogenous WNT antagonists, such as proteins from 
the Dikkopf (DKK) and secreted frizzled-related protein (sFRP) 
families (77, 86, 88, 89). Experimental models that use exogenous 
overexpression of WNT ligands or sustained nuclear accumula-
tion of β-catenin suggest that canonical WNT signaling is enough 
to trigger the expression of a fibrogenic program in fibroblasts 
(85, 86). However, depletion of β-catenin in the same model could 
not completely prevent the development of fibrosis, suggesting 
that β-catenin functions in concert with other pro-fibrotic signals 
(86). Similar findings come from pulmonary fibroblasts, in which 
FiGURe 3 | YAP and TAZ signaling. Simplified scheme showing activation 
of YAP and TAZ. (A) When the Hippo kinase complex [comprised of Serine/
threonine-protein kinases (MST1/2), MOB kinase activator 1 (MOB1), 
Salvador (SAV), and serine/threonine-protein kinases (LATS1/2)] is active, 
YAP and TAZ become phosphorylated on multiple sites, creating a so-called 
phosphodegron. (B) Both YAP and TAZ are then sequestered in the 
cytoplasm by 14-3-3 proteins or targeted for degradation by β-TrCP. (C) 
Polymerization of the F-actin cytoskeleton inhibits the activity of MST1/2, 
rendering the core kinase complex inactive (several other upstream activators 
of the core kinase complex are not shown). (D) YAP and TAZ now translocate 
to the nucleus where they associate with transcription factors such as 
Runt-related transcription factor (RUNX) and TEA domain family member 
(TEAD) to modulate transcription.
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β-catenin stabilization was not sufficient for the upregulation of 
myofibroblasts-specific genes (74). The discrepancy between 
the different studies may be due to differences in the constructs 
used to stabilize β-catenin. Taken together, it has become evident 
that regulation of β-catenin cytoplasmic/nuclear shuttling is an 
intricate process, evidenced by the complex expression pattern of 
WNT ligands in the course of fibrogenesis (71, 77, 82).
YAP/TAZ Signaling
YAP and TAZ are regarded as the main output of the Hippo 
pathway (Figure 3). YAP and TAZ have been extensively studied 
in relation to the Hippo core kinase complex, and its role in 
organ size control, stem cell fate, and cancer (90–92). Both YAP 
and TAZ contain a WW domain that binds to Pro–Pro–X–Tyr 
motifs of associated proteins (93–95). The Hippo signaling cas-
cade consists of the Ser/Thr kinases MST1 and MST2, which are 
orthologs of the Drosophila Hippo kinase (96). MST1/2 binds 
to Salvador (SAV)/WW45 to form an active enzyme complex 
that phosphorylates the MOB1A/B subunits of LATS1/2 (97). 
The activated LATS1/2–MOB1A/B complex in turn phosphoryl-
ates YAP and TAZ. The primary phosphorylation of YAP and 
TAZ triggers subsequent phosphorylation by CK1 kinases. This 
generates a “phosphodegron” recognized by β-TrCP, leading to 
YAP and TAZ polyubiquitination and subsequent proteasomal 
degradation (98). The Serine residues relevant for the inactiva-
tion of YAP and TAZ are Ser127 (Ser89 in TAZ) and S381 (S311 
in TAZ) (99, 100). When the Hippo pathway is inactive, YAP 
and TAZ are dephosphorylated and translocate to the nucleus, 
where they associate with transcription factors and other DNA-
binding proteins to modulate target gene transcription. Despite a 
similar mechanism of activation, YAP and TAZ can bind different 
transcription factors, but also display overlap as seen with the 
association with TEA DNA-binding domain (TEAD) transcrip-
tion factors (101–104). This suggests that their functions only 
partially overlap, but do share redundancy in some biological 
contexts.
The capabilities of YAP and TAZ to regulate organ growth and 
size are striking, but at the same time incompletely understood. It 
is however clear that they perform these functions, at least in part, 
as mechanical rheostats independent of the core kinase complex. 
This becomes evident in cells cultured in vitro, which show strong 
nuclear localization of YAP/TAZ in semi-confluent cultures, but 
when reaching confluence YAP and TAZ translocate to the cyto-
plasm (97). A similar biomechanical program can be observed 
in cells grown on pathologically stiff substrates or substrates that 
allow cell spreading, as they display predominantly nuclear accu-
mulation of YAP and TAZ and increased transcription of their 
target genes. By contrast, cells grown on compliant substrates 
or space limiting substrates display cytoplasmic localization of 
YAP and TAZ (105–107). F-actin polymerization determines cell 
morphology and increases in cells cultured in sub-confluence or 
on stiff substrates. Indeed, F-actin polymerization proves to be 
the link between cell spreading and YAP and TAZ nuclear trans-
location (106). The mechanical properties of YAP and TAZ were 
recently translated to myofibroblast activation and the induction 
of fibrosis. In biopsies from idiopathic pulmonary fibrosis, both 
YAP and TAZ levels are elevated, and display a predominantly 
nuclear localization, which suggests increased transcriptional 
activity (108). Moreover, YAP and TAZ knockdown in mouse 
lung and liver fibroblasts cultured on stiff substrates reduces the 
levels of proteins associated with myofibroblast differentiation 
such as pro-collagen, αSMA, and plasminogen activator inhibitor 
(PAI)1 (108, 109). Adding to this, mice heterozygous for TAZ 
show a remarkable resilience against bleomycin-induced pulmo-
nary fibrosis, possibly due to reduced levels of CCN2 (CTGF), one 
of the YAP and TAZ target genes (110). Also in cardiac fibrosis, 
YAP and TAZ have been a topic of investigation, but whether YAP 
and TAZ promote fibrogenesis remains elusive, and is probably 
dependent on the context of injury (111, 112).
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Taken together, these findings suggest that the nuclear translo-
cation of YAP and TAZ is the sum of multiple tiers of regulation 
acting in concert. Because YAP and TAZ activity is not only 
controlled by Hippo signaling but also by mechanical signals and 
other signaling cascades, we refer to YAP and TAZ signaling in 
its broader context.
Signaling Cascades Converge to Control 
Fibrotic Processes
In fibrosis, it is becoming clear that the TGF-β, WNT, and YAP 
and TAZ signaling pathways work in concert, instead of being 
isolated entities. Several studies have hinted at the inter-pathway 
cross-talk in the differentiation of myofibroblasts. For instance, in 
lung fibrosis, protein levels of both YAP and TAZ are increased 
and have increased nuclear localization (108). This corresponds 
to the increased levels of nuclear β-catenin and phosphorylated 
R-Smads found in fibrotic tissues. During skin wound healing 
in mice, both YAP and TAZ are increased upon injury and 
translocated to the nucleus. Moreover, TGF-β1 levels are also 
increased in the dermis, suggesting a link between activation of 
YAP and TAZ and the production of TGF-β1 (113). Adding to 
this, YAP- and TAZ-deficient fibroblasts are less reactive to TGF-
β stimulation in vitro, produced less ECM, have lower expression 
of myofibroblast markers PAI1 and αSMA, and show lower 
contractile capabilities (108).
The mechanisms through which these pathways communicate 
are diverse and range from modulating the availability of growth 
factors and the availability of membrane bound receptors to 
nuclear entry and activation of transcription factors (Figure 4).
Pathways Govern Agonist and Antagonist 
expression of Other Pathways
The most straightforward form of cross-talk between signaling 
cascades occurs when activity of one pathway enhances the 
production of agonists or antagonists of the second. This type of 
cross-talk can create a feed-forward or feedback loop to enhance 
or attenuate, respectively, the transcriptional activity of another 
signaling cascade. For instance, stimulation of fibroblasts with 
WNT3a enhances the expression of TGF-β1 and subsequent phos-
phorylation of the MH2 domain of Smad2 (114). Consistently, 
absence of WNT signaling through LRP5 in bleomycin-induced 
lung fibrosis decreases the expression of TGF-β1 and attenuates 
the fibrotic response (115). Reconstitution of active TGF-β1 
signaling in LRP5-deficient mice overrides the protective effects 
of abrogated WNT signaling. Moreover, it was found that TGF-β 
also enhances WNT signaling through the inhibition of DKK1 
(116). Reduced expression of DKK1 enhances the stability and 
nuclear accumulation of β-catenin in both epithelial cells and 
fibroblasts, whereas reconstitution of DDK1 in  vivo attenuates 
TGF-β-induced fibrosis. This allows cells to communicate over 
a certain distance and influence the microenvironment of its 
neighboring cells. Despite the strong effects of altered growth 
factor signaling, this is often not enough to modulate complex 
fibrogenic responses. To achieve this kind of complexity, direct 
interaction between signaling components is required.
Cytoplasmic Retention and Degradation of 
Transcriptional Modulators
TGF-β, WNT, and YAP/TAZ output activity all rely on a general 
mechanism: the nuclear translocation of its transcriptional 
modulators. To prevent continuous activation, the cell has several 
means to prevent spontaneous nuclear entry or binding to the 
DNA. For instance, Smad proteins continuously shuttle between 
the cytoplasm and the nucleus (33). Without tail-phosphorylation 
by the TGF-β type I receptor, Smads cannot interact with Smad4 
and are unable to engage the DNA. Instead, they are phosphoryl-
ated in the linker region by CDK8/9 and GSK3 which renders 
them susceptible for polyubiquitination and degradation (31). By 
contrast, β-catenin and YAP and TAZ are sequestered in protein 
complexes with E-cadherin or 14-3-3 proteins, respectively, or 
directly targeted for proteasomal degradation by associating with 
β-TrCP (60, 94, 97).
Recent studies highlighted that extensive cross-talk occurs on 
the level of cytoplasmic retention and degradation. One example 
of cross-talk between the YAP and TAZ, and TGF-β pathways 
is through the interaction with Smad7. As mentioned above, 
activated Smad proteins need to form a complex with Smad4 in 
order to become transcriptionally active modules. To regulate the 
Smad activation cycle, the TGF-β pathway uses Smad7 to form 
a negative feedback loop via various mechanisms. First, Smad7 
can associate with the TGF-β type I receptor. Consequently, 
R-Smad phosphorylation and complex formation between 
R-Smads and Smad4 are inhibited (117). Smad7 also recruits E3 
ubiquitin ligases, such as Smurf1 and Smurf2, to initiate receptor 
ubiquitination and degradation of the receptor complex. This 
self-regulating layer of the TGF-β signaling cascade can be linked 
to YAP and TAZ signaling, as YAP was found to associate with 
Smad7 at the type I receptor (118). By binding to YAP, Smad7 
has a higher affinity for the type I receptor and increases its 
repressive effects on TGF-β signaling. Another line of evidence 
revealed that Smad7 interacts with β-catenin to promote Smurf2-
induced mediated ubiquitination and degradation, attenuating 
WNT activity in the skin (119). By contrast, in cancer epithelial 
cells it was found that Smad7 promotes the stability of β-catenin 
by enhancing its association with E-cadherin at the plasma 
membrane (120). Moreover, upon TGF-β stimulation, the WNT 
scaffold protein Axin can form a complex with Smad7 and the E3 
ubiquitin ligase Arkadia to promote Smad7 degradation (121). 
These conflicting reports underline that Smad7 may act as repres-
sor or enhancer of cellular signaling depending on the cell type 
and environmental context.
As mentioned above, the type I receptor initiates phosphoryla-
tion of R-Smads, a process that is regulated through the interac-
tion with several adaptor proteins. Interestingly, in unstimulated 
fibroblasts, Axin facilitates the binding of Smad3 with the type 
I receptor, independent from the adapter protein SARA (122). 
Upon TGF-β simulation, Axin promotes the tail-phosphorylation 
of Smad3 and subsequently dissociates from the type I receptor. 
Depletion of Axin results in decreased expression of TGF-β 
responsive genes such as PAI1, suggesting that Axin mediates 
cytoplasmic cross-talk between the TGF-β and WNT pathways 
which promotes the transcription of pro-fibrotic genes.
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Recently it was found that TAZ also communicates with WNT 
signaling through the interaction of TAZ and β-catenin in the 
cytoplasm (123). In a WNT-off state, both β-catenin and TAZ 
associate with β-TrCP and are ubiquitinated and degraded in the 
FiGURe 4 | The TGF-β, wNT, and YAP/TAZ signaling pathways converge. 
Schematic overview of the molecular cross-talk between components of the 
TGFβ, WNT, and YAP/TAZ pathways. (A) Upon TGF-β stimulation, Axin 
promotes the tail-phosphorylation of Smad3. (B) Axin also promotes the 
degradation of inhibitory Smad7, thereby further enhancing the TGF-β signal. 
Smad7 can associate with both YAP and β-catenin. Binding of YAP to Smad7 
increases the affinity for the type I receptor and increases the repressive effects 
on TGF-β signaling. Smad7 binding with β-catenin can mediate both 
degradation and stabilization of β-catenin. (C) TAZ inhibits the phosphorylation 
of disheveled (DVL) by casein kinase (CK)1, providing either positive or negative 
feedback depending on the WNT ligand present. (D) The active Hippo core 
kinase complex phosphorylates both YAP and TAZ creating a phosphodegron. 
Phosphorylated YAP and TAZ are either sequestered by 14-3-3 proteins or 
associate with the β-catenin destruction complex. In the destruction complex, 
YAP and TAZ are necessary for docking of β-TrCP to the complex. (e) 
Phosphorylated YAP also associates with β-catenin to inhibit its nuclear 
translocation and promote its degradation. (F) Upon WNT activation, the 
destruction complex is inhibited because YAP and TAZ dissociate from the 
complex. As later event, the destruction complex is sequestered by the LRP/
Frizzled/DVL receptor complex and targeted for degradation in the 
microvascular bodies. (G) F-actin polymerization inactivates the core kinase 
complex, causing YAP and TAZ to be dephosphorylated. Concurrently, β-catenin 
is not degraded by the inactive destruction complex, so that newly synthesized 
β-catenin accumulates in the cytoplasm. (H) The activated Smad complex 
associates with YAP or TAZ and translocates to the nucleus. Free and stabilized 
β-catenin also translocates to the nucleus. (i) In the nucleus, the transcription 
factors may co-localize at the chromatin depending on the context to govern 
transcription of myofibroblast related genes. (J) At the end of the transcription 
cycle, transcription factors are degraded in the nucleus, or translocate back to 
the cytoplasm for either degradation or a new round of activation.
proteasome. This process requires active GSK3 phosphorylation 
of the β-catenin phosphodegron. Upon WNT stimulation, GSK3 
dissociates from the destruction complex, β-catenin is dephos-
phorylated and unable to bind to TAZ. Thus, WNT stimulation 
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induces the stability and nuclear localization of its own transcrip-
tional modulator, β-catenin, as well as TAZ.
Furthermore, inactive YAP and TAZ form a complex together 
with β-catenin, GSK3, and Axin1 (124). Cytoplasmic YAP/TAZ 
specifically bind Axin in absence of WNT signals. In this case, 
Axin facilitates the function of cytoplasmic anchor, as Axin deple-
tion results in a rapid nuclear accumulation of YAP/TAZ. Indeed, 
stimulation by WNT3a causes dissociation of YAP/TAZ from the 
destruction complex after which they translocate to the nucleus, 
and modulate transcription of TEAD target genes. Vice  versa, 
as part of the destruction complex, YAP/TAZ are needed for 
the docking of β-TrCP to the destruction complex. By releasing 
YAP/TAZ upon WNT stimulation, β-TrCP cannot bind to the 
destruction complex and ubiquitinate β-catenin. Furthermore, it 
was found that protein kinase C zeta (PKCζ) associates with the 
destruction complex and can phosphorylate YAP and β-catenin on 
several residues, adding to quick proteasomal degradation (125).
Next to its function in the destruction complex, it was found 
that TAZ binds to the PY and PDZ domains of DVL2 upon 
stimulation with WNT3a (126). TAZ binding inhibits the phos-
phorylation of DVL2 by CK1, which results in reduced β-catenin-
mediated activity of LEF/TCF transcription. Interestingly, 
WNT3a and WNT5a  –  which in part have opposite functions 
in β-catenin stabilization – both induce the phosphorylation of 
CK1, suggesting that TAZ binding to DVL2 may have different 
outcomes depending on the WNT isoform and receptor pair 
present (127).
Furthermore, it was found that YAP too fulfills multiple 
roles in YAP/WNT cross-talk. By directly binding to β-catenin, 
phosphorylated YAP prevents nuclear translocation of β-catenin 
and subsequent transcription of LEF/TCF target genes (128). This 
process is dependent on the activity of the Hippo core kinase 
complex, as increased Hippo activity induces phosphorylation of 
YAP and concomitantly reduces levels of β-catenin in the nucleus. 
Evidence thus shows that the transcriptional modulators of the 
TGF-β, WNT, and YAP/TAZ pathways are integral factors in the 
cross regulation between these pathways. Cytoplasmic retention 
of transcription factors and transcriptional activators proves to be 
an ingenious system through which the three different pathways 
tightly regulate their own and each other’s activity.
Nuclear Shuttling and Transcriptional 
Modulation
The original view on growth factor signaling described the 
nuclear accumulation of transcriptional modulators solely as a 
consequence of ligand-mediated activation. In the absence of a 
growth factor ligand, Smads and β-catenin were thought to reside 
exclusively in the cytoplasm and translocate only to the nucleus 
upon receptor activation. We now know that transcription factor 
shuttling is not as black and white as once proposed. Without 
stimulation, R-Smad proteins continuously shuttle between the 
nucleus and cytoplasm, but display a significant higher concen-
tration in the cytoplasm (129). It is thought that R-Smads reside 
in the cytoplasm, until TGF-β stimulation releases them for 
nuclear translocation, enhances their affinity for nuclear importin 
proteins, and induces nuclear anchoring. In the case of canonical 
WNT signaling, β-catenin levels are maintained low due to deg-
radation in absence of WNT signals, although β-catenin can be 
observed in both the cytoplasm and the nucleus. Recent develop-
ments reveal that the fold-change in β-catenin levels after WNT 
stimulation is more important for transcriptional modulation 
than the absolute levels of β-catenin (130). This finding suggests 
that even in cells with low basal β-catenin levels, slight changes in 
nuclear β-catenin are sufficient to initiate transcriptional changes. 
Nuclear accumulation of YAP and TAZ is governed by the activity 
of the Hippo signaling cascade as well as biomechanical signals 
that are relayed from outside the cell. It is becoming clear that fine 
tuning of nucleocytoplasmic shuttling is not just mediated by a 
single signaling pathway, but rather by the cross-talk of several 
components of the TGF-β, WNT, and YAP/TAZ cascades.
In fibrosis, epithelial to mesenchymal transition (EMT) 
describes the process of epithelial cells that undergo transdiffer-
entiating toward a myofibroblast-like phenotype, a phenomenon 
observed in both cancer metastasis and fibrosis (9, 131, 132). Upon 
injury, epithelial cells lose their characteristic cellular junctions 
and acquire a spindle-like morphology. Cells undergoing EMT 
often show increased motility, de novo expression of αSMA, and 
elevated expression of ECM components, such as collagens and 
fibronectin. Also during EMT, several studies have provided evi-
dence that TGF-β, WNT, and YAP/TAZ interact with each other 
to drive the transformation toward a mesenchymal-like cell type.
One of the first studies, describing the integration of YAP/TAZ 
and TGF-β signaling in nucleocytoplasmic shuttling, found that 
TAZ interacts with Smad2/4 and Smad3/4 complexes in epithelial 
cells (133). The coiled-coil domain in the C-terminal region of 
TAZ binds to the MH1 domain of Smad2/3 and thereby pro-
motes the nuclear accumulation of Smad2/3 and increases their 
transcriptional activity on target genes such as PAI1 and SMAD7. 
Interestingly, low levels of TAZ promote nuclear accumulation, 
but when the concentration of TAZ increased, it is predominantly 
located in the cytoplasm and nuclear localization of Smad2/3 
is blocked. This suggests that Smad accumulation is strongly 
dependent on the expression levels and activation status of TAZ.
Similar findings were obtained for YAP, which forms a com-
plex with Smad3, TEAD, and p300 on the CCN2 promoter in 
mesothelioma cells (134). Knock down of YAP results in attenu-
ated expression of endothelin1 (ET1) and CCN2, whereas no 
immediate differences are seen in the expression of fibronectin 
and collagens, suggesting that YAP controls the expression of 
a subset of TGF-β responsive genes. Moreover, levels of metal-
loproteinase 2 (MMP2) are increased upon YAP knock down, 
strengthening the hypothesis that YAP, together with Smads, 
governs a pro-fibrotic phenotype. These findings were corrobo-
rated in mammary epithelial cells, as YAP/TAZ associates with 
Smad2/3 and TEADs (135).
A question that then arises is whether transcriptional modu-
lators only need each other for nuclear entry, or also associate 
with each other at specific promoter or enhancer regions to 
modulate transcription. Interestingly, during EMT in alveolar 
epithelial cells, simultaneous stimulation by TGF-β and WNT 
ligands has synergistic effects on the expression of αSMA as well 
as the activity of LEF/TCF responsive elements (136). TGF-β 
alone induces nuclear translocation of β-catenin by inactivating 
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GSK3-mediated degradation, which is further enhanced by WNT 
stimulation. Delicate ChIP-re-ChIP experiments revealed that 
β-catenin and Smad3 co-localize at the SBE1 containing region 
of the αSMA promoter, in a CBP-dependent fashion. These 
findings are supported by co-localization of β-catenin, Smad3, 
and CBP in nuclei of epithelial cells in idiopathic pulmonary 
fibrosis biopsies. Other reports contradict these findings and 
propose that β-catenin induces the expression of αSMA through 
interaction with myocardin-related transcription factor (MRTF), 
a process inhibited by Smad3 (52, 137). One explanation for these 
conflicting results may be the differences in experimental setup 
and the different species studied.
Smads and β-catenin were also found to interact on other 
genes involved in fibrogenesis. As proof of principle, TGF-β 
and WNT3a synergistically enhanced the promoter activity of 
sequences containing both SBE and LEF/TCF responsive ele-
ments (138). Co-stimulation resulted in a unique expression 
profile distinct from that seen after stimulation with single 
growth factors. Interestingly, recent developments describe how 
YAP can compete with Smad2/3 for promoter occupancy in the 
transcription of genes involved in mesendoderm differentiation. 
Gene transcription strongly depends on the phosphorylation 
status of RNA polymerase II (RNAPII) [reviewed in Ref. (139)]. 
Briefly, phosphorylation of RNAPII on Ser5 is important for 
the initiation of transcription, whereas subsequent phospho-
rylation on Ser2 and Ser7 are crucial for the elongation steps 
of transcription. β-catenin and LEF-1 associate with enhancer 
regions of mesendodermal genes such as MIXL1 and EOMES 
and recruit Ser5 phosphorylated RNAPII to initiate transcrip-
tion (140). Upon activin stimulation, Smad2/3 localize to the 
promoter region of these genes to enhance the phosphorylation 
of Ser2 and Ser7 on RNAPII and thereby promote elongation of 
transcription. YAP was found to actively inhibit this process by 
recruitment of the negative elongation factor NELF. Knockdown 
of YAP reduces the occupancy of NELF and enhances the phos-
phorylation on Ser2 and Ser7 at target genes, which promotes 
transcription. Although these results do not directly link to 
myofibroblast function, they have significant implications on the 
mechanism by which YAP regulates gene transcription. Future 
research will reveal if similar mechanisms apply to the regulation 
of myofibroblast-related genes.
Taken together, TGF-β, WNT, and YAP/TAZ signals converge 
by modulating the nuclear accumulation and transcriptional 
activity of their transcription factors. Furthermore, the outcome 
of this type of cross-talk is not only dependent on the concen-
tration of transcription factors but also on the availability of 
co-activators and co-repressors, chromatin conformation, and 
the phosphorylation status of RNAPII, which may vary from one 
cell type to another (31, 140).
Transcription Factor Recycling
The final stage of the signal transduction cascades involves the 
process of transcription factor recycling. In the case of Smad pro-
teins, tail-phosphorylation of the MH2 domain induces nuclear 
accumulation. Whether nuclear R-Smads engage in transcription 
or are targeted for nuclear exit and proteasomal degradation relies 
on a series of phosphorylation and dephosphorylation events by 
multiple kinases and phosphatases [reviewed in Ref. (141)]. The 
variety of kinases and phosphatases introduces another level 
of complexity in the regulation of Smad action, and is greatly 
dependent on signaling through other pathways at a specific place 
and time.
One of the examples, through which other pathways interact 
with Smad recycling describes the temporal regulation by CDK8/9 
and GSK3. First CDK8/9 phosphorylate Smad1 on Ser206 and 
Ser214, which allows binding with YAP and simultaneously 
triggers phosphorylation by GSK3 on Thr202 and Ser210. The 
latter phosphorylation events cause YAP to dissociate and Smurf2 
to bind with Smad1, and initiate ubiquitination (32). Although 
Smad1 is not activated by TGF-β but rather by BMPs, one can 
envision identical mechanisms in the recycling of canonical 
R-Smads by Nedd4L (31, 142). Whether the association of TAZ 
with Smad2/3 has similar effects on their recycling remains to 
be determined. As mentioned above, YAP is able to enhance the 
repressive functions of Smad7 at the type I receptor. Interestingly, 
Smad7 has also been found to inhibit TGF-β signaling in the 
nucleus, where it can use its MH2 domain to bind to DNA 
sequences containing SBEs (143). DNA bound Smad7 competes 
with Smad2/Smad4 complexes, thus, directly impairing the tran-
scription of TGF-β responsive genes such as PAI1. Whether the 
interactions between YAP and Smad7 are of importance in this 
process remain to be elucidated.
Therapeutic Targeting at the Cross-Roads
Remarkable progress in both biology and pharmacology has led 
to advances in the development of anti-fibrotic therapies. Many 
of these therapies aim to target the usual suspects such as ligands 
and receptors of the TGF-β and WNT signaling cascades using 
antagonistic antibodies or small-molecule inhibitors. Although 
the therapeutic efficacy in animal models proves promising (78), 
trials often fail to achieve significance in clinical endpoints or 
suffer from severe adverse effects (73) with the exception of one 
recent study in systemic sclerosis (144). The discrepancy in effi-
cacy between rodents and humans suggests that animal models 
poorly mimic the pathophysiology of human fibrotic disorders. 
As we gain insight in the molecular mechanisms that link the 
TGF-β, WNT, and YAP/TAZ cascades, we come to understand 
the challenges and pitfalls of targeting one specific signaling 
pathway [thoroughly reviewed in Ref. (19, 145–147)]. We have 
seen that signaling cascades are complex and that many pathway 
components fulfill multiple functions. Because TGF-β, WNT, and 
YAP/TAZ signals have distinct functions in different cell types 
and tissues, specific targeting of the fibrotic lesion is crucial. The 
temporal properties of signal transduction in different phases of 
disease and homeostasis pose another difficulty in the admin-
istration of pathway-wide modulating agents. It is therefore not 
just a matter of up- or downregulation. For example, targeting 
of TGF-β or WNT signaling with neutralizing antibodies may 
have widespread effects on the functioning of several components 
of the TGF-β, WNT, and YAP and TAZ signaling pathways, as 
well as numerous other growth factor cascades. To circumvent 
the wide-spread effects of growth factor inhibition and limit 
September 2015 | Volume 2 | Article 5910
Piersma et al. Signaling in fibrosis: pathways converge
Frontiers in Medicine | www.frontiersin.org
adverse effects, we increasingly depend on the development of 
small-molecule intracellular inhibitors.
The small-molecule intracellular inhibitor LY2157299 specifi-
cally targets the kinase pocket of the type I receptor of the TGF-β 
cascade without inhibiting the type II receptor and thereby 
attenuates Smad2/3-dependent transcription of target genes 
(145). However, LY2157299 has not been studied in clinical trials 
to halt or reverse fibrosis. Examples of small-molecule intracel-
lular inhibitors for the WNT pathway, such as PKF115–584 and 
CGP049090 (148), act on the association between β-catenin 
and LEF/TCF transcriptions factors. Other strategies focus on 
inhibition of the PDZ domain of DVL or the transcriptional co-
activators CBP and p300 (145). By inducing a shift from β-catenin 
association with p300 to CBP, genes such as COL1A1 may be 
negatively regulated (149). However, other studies report that 
inhibition of β-catenin–CBP also ameliorates fibrosis, suggesting 
that there is no such thing as pure “good” and “bad” β-catenin 
signaling (73, 78). As YAP and TAZ have but recently been 
linked to fibrogenesis, no clinical trials have been performed. 
Thus, whether targeting of YAP and TAZ is a fruitful strategy 
against fibrosis progression remains to be elucidated. One of the 
challenges in the targeting of YAP and TAZ is that they do not 
possess catalytic domains, but rather depend on specific protein 
binding domains for the interaction with their binding partners 
such as LATS1/2, Src family kinases, and TEADs. Nonetheless, 
a recent study described a potent inhibitor of YAP–TEAD: the 
benzoporphyrin derivative verteporfin (150). Verteporfin is 
currently used in the clinic for the treatment of macular degen-
eration, which makes it appealing for the use in clinical trials for 
fibrosis. Although inhibition of the YAP–TEAD complex seems a 
promising anti-fibrotic strategy, as several pro-fibrotic genes are 
not under control of TEADs, this may prove not to be the best 
approach.
The disadvantages of pathway-wide molecular inhibitors 
challenge the scientific community to develop specific targeting 
strategies against intracellular processes and protein–protein 
interactions. The increasing insight in the molecular cross-talk 
between signaling cascades adds new possibilities in drug 
development. Additionally, by focusing on the elucidation of 
the crystal structures of protein complexes, we can pursue the 
rational design of novel small molecular inhibitors to interfere 
at the cross-roads of signal transduction cascades.
Conclusion
Recent advancements in the field of TGF-β, WNT, and YAP/TAZ 
signaling have revealed that these signaling entities do not act 
alone. The notion that pathway components can have multiple 
and even opposed functions within one cell partly explains how 
the inhibition of a single molecular target often does not result 
in the desired therapeutic effect. This does not only add to the 
mere understanding of fibrotic processes, but also promotes the 
necessity to develop highly specific small-molecule intracellular 
inhibitors that act on protein–protein interactions at the cross-
roads of signaling cascades. It should be noted that several of the 
studies described in this review used artificial ectopic expression 
of the proteins investigated. This may introduce artifacts that can 
influence the activity and functionality of the signaling cascades 
involved. Thus, more detailed studies in representative models for 
fibrosis focusing on endogenous proteins are required to com-
pletely understand the molecular cross-talk in vivo. Broadening 
our view on signal transduction will provide a better understand-
ing of how a limited set of growth factors is able to govern the 
complex processes that underlie the physiology and pathology of 
fibrotic disorders.
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